Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 9/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | VEGFA | P15692 | 2/20 | 0.39 |
| ▸ | FLT1 | P17948 | 2/20 | 0.39 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1508960 | 0.92 | EGLN1 (0.53) | EGLN1POLBMAPTGAASMN1; SMN2 | |
| SCHEMBL14735698 | 0.83 | MAPT (0.46) | EGLN1POLBMAPTGAASMN1; SMN2 | |
| SCHEMBL1509146 | 0.81 | EGLN1 (0.49) | EGLN1MAPTGAA | |
| SCHEMBL966853 | 0.81 | KMT2A (0.53) | EGLN1POLBMAPTGAASMN1; SMN2 | |
| SCHEMBL8880594 | 0.79 | MEN1 (0.50) | EGLN1POLBMAPTGAASMN1; SMN2 | |
| SCHEMBL8883714 | 0.79 | MEN1 (0.50) | EGLN1POLBMAPTGAASMN1; SMN2 | |
| SCHEMBL8882701 | 0.79 | MEN1 (0.50) | EGLN1POLBMAPTGAASMN1; SMN2 | |
| SCHEMBL14735807 | 0.79 | MAPT (0.43) | EGLN1POLBMAPTGAASMN1; SMN2 | |
| SCHEMBL8881979 | 0.79 | MEN1 (0.50) | EGLN1POLBMAPTGAASMN1; SMN2 | |
| SCHEMBL20336258 | 0.77 | GAA (0.51) | EGLN1POLBNAMPTMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298301-A2 | Medicaments for increasing endogenous Erythropoietin (EPO) | Fibrogen, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |